Patents by Inventor Tyler Jacks
Tyler Jacks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240163283Abstract: Embodiments of the present invention provide a system for implementing authentication control protocols via components of entity device. In particular, the system may be configured to determine initiation of a resource interaction by a user at an entity device, control one or more components of the entity device to cause the entity device to capture a real-time image of the user, compare the real-time image captured via the entity device with an updated enhanced user image stored in a data file of the user, in response to comparing the real-time image with the updated enhanced user image, determine if the real-time image matches the updated enhanced user image, and implement one or more authentication control protocols based on determining if the real-time image matches the updated enhanced user image.Type: ApplicationFiled: November 10, 2022Publication date: May 16, 2024Applicant: BANK OF AMERICA CORPORATIONInventors: Christopher Daniel Birch, Sophie Morgan Danielpour, Susan R. Hart, Son Huynh, Tyler Keith Prothro, Shannon Sabina Rolinger, Amado Jose Martinez Suarez, Stephen Jack Williams
-
Publication number: 20240160722Abstract: Embodiments of the present invention provide a system for identifying and redirecting incoming unauthorized data access requests. The system is configured for continuously monitoring one or more incoming data access requests from one or more sources, identifying that a data access request of the one or more incoming data access requests is an unauthorized request, redirecting the data access request to a controlled environment, performing one or more actions in the controlled environment to capture one or more interactions associated with the data access request within the controlled environment, and automatically generating one or more controls to secure a real-time environment based on the one or more interactions captured within the controlled environment.Type: ApplicationFiled: November 10, 2022Publication date: May 16, 2024Applicant: BANK OF AMERICA CORPORATIONInventors: Christopher Daniel Birch, Sophie Morgan Danielpour, Susan R. Hart, Son Huynh, Tyler Keith Prothro, Shannon Sabina Rolinger, Amado Jose Martinez Suarez, Stephen Jack Williams
-
Publication number: 20240127241Abstract: Systems, computer program products, and methods are described herein for electronic resource transfer authentication via a user characteristic data verification engine. The system receives a request to transfer electronic resources from a first endpoint device of a merchant. The system then identifies a resource vehicle owner associated with the electronic resource transfer, identifies at least one second endpoint device, then transmits a request for verification from the entity to the at least one second endpoint device, utilizing an application programming interface. The user characteristic feedback hardware of the at least one second endpoint device collects identifier data from the user of the at least one second endpoint device, and a user characteristic data verification engine is initiated and thereafter determines a binary identification output. An entirety of the electronic resources are distributed to the merchant based on the binary identification output.Type: ApplicationFiled: October 12, 2022Publication date: April 18, 2024Applicant: BANK OF AMERICA CORPORATIONInventors: Christopher Daniel Birch, Sophie Morgan Danielpour, Susan R. Hart, Son Huynh, Tyler Keith Prothro, Shannon Sabina Rolinger, Amado Jose Martinez Suarez, Stephen Jack Williams
-
Publication number: 20240043934Abstract: Described herein are pancreatic ductal adenocarcinoma (PDAC) signatures and methods of detecting the same in a sample from heterogeneity-score a subject. Also described herein, are methods of methods of diagnosing, prognosing, and/or treating PDAC in a subject that can include detecting one or more of the PDAC signatures.Type: ApplicationFiled: August 22, 2021Publication date: February 8, 2024Inventors: Aviv Regev, William Hwang, Karthik Jagadeesh, Jimmy Guo, Tyler Jacks, Hannah Hoffman
-
Patent number: 11739156Abstract: The present invention discloses novel methods, compositions, and uses thereof for removing or overcoming immunosuppression. More specifically, the methods and compositions disclosed herein target effector Treg cells by modulating ST2 and/or IL-33 signaling using pharmaceutical inhibitors and/or genetic ablation, whereby the levels and/or activities of effector Treg cells in a tumor microenvironment are inhibited, and the infiltration of effector CD8+ cytotoxic T cells into tumor microenvironment increases. As a result, tumor growth is inhibited and tumor volume is reduced. The present invention also provides methods for identifying and isolating effector Treg cells in a population of heterogeneous cells.Type: GrantFiled: January 6, 2020Date of Patent: August 29, 2023Assignee: The Broad Institute, Inc. Massachusetts Institute of TechnologyInventors: Amy Li, Rebecca H. Herbst, Aviv Regev, Tyler Jacks, David Canner
-
Patent number: 11331269Abstract: It has been discovered that lung tumor growth is associated with a dysregulation of the local microbiota, including an increased total bacterial load and reduced bacterial diversity in the airway. In the lungs, commensal bacteria, which are otherwise non-pathogenic and colonize pulmonary tissue at a much lower density in healthy individuals, provoke chronic inflammation and exacerbation of lung cancer through tumor-infiltrating immune cells. Thus, targeting the lung microbiota and its responding immune pathways is useful in treating lung cancer. Disclosed are compositions and methods targeting the lung microbiota and its responding immune pathways in a subject by specific targeting of commensal bacteria in the subject. Typically, the methods involve administering an effective amount of one or more therapeutics such as an antibiotic that reduces the local bacterial load, blocks or depletes tumor-infiltrating immune cells, and/or locally inhibits one or more cytokines or chemokines.Type: GrantFiled: June 21, 2019Date of Patent: May 17, 2022Assignees: Massachusetts Institute of Technology, The Broad Institute, Inc.Inventors: Chengcheng Jin, Georgia Lagoudas, Paul Blainey, Tyler Jacks
-
Publication number: 20210361603Abstract: The present disclosure relates to a method of treating a subject having cancer that includes selecting a subject having cancer associated with a deregulated NRF2/KEAP1 pathway and administering to the selected subject one or more inhibitors comprising a glutamine transporter inhibitor; a GPD2 inhibitor; or combination(s) thereof.Type: ApplicationFiled: February 6, 2018Publication date: November 25, 2021Applicants: New York University, Massachusetts Institute Of TechnologyInventors: Thales PAPAGIANNAKOPOULOS, Tyler JACKS, Rodrigo ROMERO
-
Publication number: 20210128338Abstract: Technical garments including joint stabilization socks, sleeves, and other garments are disclosed. The exemplary garments disclosed herein include regions with material properties, such as tensile strengths, that are different from other regions of the garment. Particular regions of the exemplary garments include interwoven materials with substantially high tensile strengths for providing resistance/compression to targeted body parts (e.g., ankles, knees, shoulders, etc.) for preventing undesirable movement (e.g., that mimics medically-relevant taping patterns). In particular embodiments, the regions with higher tensile strengths are interwoven or integrated into a base material, such that the garment can be comfortably worn while also providing compression and support to targeted body parts.Type: ApplicationFiled: August 22, 2018Publication date: May 6, 2021Inventors: Partha Sarathy UNNAVA, Tyler Jack Prescott HARMON
-
Publication number: 20200216551Abstract: The present invention discloses novel methods, compositions, and uses thereof for removing or overcoming immunosuppression. More specifically, the methods and compositions disclosed herein target effector Treg cells by modulating ST2 and/or IL-33 signaling using pharmaceutical inhibitors and/or genetic ablation, whereby the levels and/or activities of effector Treg cells in a tumor microenvironment are inhibited, and the infiltration of effector CD8+ cytotoxic T cells into tumor microenvironment increases. As a result, tumor growth is inhibited and tumor volume is reduced. The present invention also provides methods for identifying and isolating effector Treg cells in a population of heterogeneous cells.Type: ApplicationFiled: January 6, 2020Publication date: July 9, 2020Inventors: Amy Li, Rebecca H. Herbst, Aviv Regev, Tyler Jacks, David Canner
-
Publication number: 20200078296Abstract: It has been discovered that lung tumor growth is associated with a dysregulation of the local microbiota, including an increased total bacterial load and reduced bacterial diversity in the airway. In the lungs, commensal bacteria, which are otherwise non-pathogenic and colonize pulmonary tissue at a much lower density in healthy individuals, provoke chronic inflammation and exacerbation of lung cancer through tumor-infiltrating immune cells. Thus, targeting the lung microbiota and its responding immune pathways is useful in treating lung cancer. Disclosed are compositions and methods targeting the lung microbiota and its responding immune pathways in a subject by specific targeting of commensal bacteria in the subject. Typically, the methods involve administering an effective amount of one or more therapeutics such as an antibiotic that reduces the local bacterial load, blocks or depletes tumor-infiltrating immune cells, and/or locally inhibits one or more cytokines or chemokines.Type: ApplicationFiled: June 21, 2019Publication date: March 12, 2020Inventors: Chengcheng Jin, Georgia Lagoudas, Paul Blainey, Tyler Jacks
-
Publication number: 20190365719Abstract: It has been established that exposure to cytotoxic doses of HSP90 inhibitor is broadly immunosuppressive, whereas continuous exposure to low-dosages of the same inhibitor exerts anti-tumor activity. The anti-tumor activity is mediated by the host immune system. Compositions and methods for continuous, low-dose exposure to HSP90 inhibitors in combination with one or more immunostimulatory agents for the treatment of cancer are described. Typically, the HSP90 inhibitor is administered in an amount that is between 1% and 20% of the clinically-determined maximum tolerate dose. The immunostimulatory agent can be administered simultaneously with the HSP90 inhibitor, or at some time before or after the HSP90 inhibitor. Compositions including a sub-toxic dose of HSP90 inhibitor in combination with an immunostimulatory agent in an amount effective to treat cancer are also provided.Type: ApplicationFiled: June 3, 2019Publication date: December 5, 2019Inventors: Tyler Jacks, Alexander Jaeger, Sandro Santagata, Luke Whitesell, Susan Lindquist
-
Patent number: 10206687Abstract: The present disclosure discusses systems and methods for controlling a hemorrhage. The hemorrhage control device can include a harness that is worn around an upper junctional area and a lower junctional area of a user. The hemorrhage control device can also include a compression device that is configured to reversibly couple with the harness. The compression device can include a compression puck and a handle. The handle can be coupled with the harness. When rotated the handle can constrict the harness around the upper junctional area or the lower junctional area. The constriction of the harness can also cause the compression puck to compress the upper junctional area or the lower junctional area.Type: GrantFiled: April 21, 2015Date of Patent: February 19, 2019Assignee: ARMR SYSTEMS LLCInventors: Tyler Jack Prescott Harmon, Yegor Podgorsky, Chibueze Joseph Ihenacho
-
Publication number: 20170049459Abstract: The present disclosure discusses systems and methods for controlling a hemorrhage. The hemorrhage control device can include a harness that is worn around an upper junctional area and a lower junctional area of a user. The hemorrhage control device can also include a compression device that is configured to reversibly couple with the harness. The compression device can include a compression puck and a handle. The handle can be coupled with the harness. When rotated the handle can constrict the harness around the upper junctional area or the lower junctional area. The constriction of the harness can also cause the compression puck to compress the upper junctional area or the lower junctional area.Type: ApplicationFiled: April 21, 2015Publication date: February 23, 2017Inventors: Tyler Jack Prescott Harmon, Yegor Podgorsky, Chibueze Joseph Ihenacho
-
Patent number: 7622630Abstract: Chimeric nonhuman mammals useful as inducible spontaneous cancer models are disclosed. The nonhuman mammals are obtained by introducing one or more genetically modified embryonic stem (ES) cells into an early stage embryo, and then implanting the manipulated embryo into a surrogate mother. The ES cells contain a recombinant oncogene, and also may contain a genetic mutation that deletes or inactivates a tumor suppressor gene. Models of different types of cancer are produced by introducing different combinations of genetic mutations into the ES cells that are introduced into the early stage embryo.Type: GrantFiled: August 27, 2004Date of Patent: November 24, 2009Assignee: AVEO Pharmaceuticals, Inc.Inventors: Joerg Heyer, Murray Robinson, William Rideout, III, Ronald Depinho, Steven C. Clark, Yinghui Zhou, Tyler Jacks, Ronan C. O'Hagan
-
Patent number: D883651Type: GrantFiled: January 3, 2018Date of Patent: May 12, 2020Assignee: BETTER WALK, INC.Inventors: Tyler Jack Prescott Harmon, Partha Sarathy Unnava, Pranav Chunduri
-
Patent number: D890938Type: GrantFiled: August 22, 2018Date of Patent: July 21, 2020Assignee: BETTER WALK, INC.Inventors: Partha Sarathy Unnava, Tyler Jack Prescott Harmon
-
Patent number: D895815Type: GrantFiled: August 22, 2018Date of Patent: September 8, 2020Assignee: BETTER WALK, INC.Inventors: Partha Sarathy Unnava, Tyler Jack Prescott Harmon
-
Patent number: D905257Type: GrantFiled: April 7, 2020Date of Patent: December 15, 2020Assignee: BETTER WALK, INC.Inventors: Tyler Jack Prescott Harmon, Partha Sarathy Unnava, Pranav Chunduri
-
Patent number: D991464Type: GrantFiled: August 6, 2020Date of Patent: July 4, 2023Assignee: BETTER WALK, INC.Inventors: Partha Sarathy Unnava, Tyler Jack Prescott Harmon
-
Patent number: D1010834Type: GrantFiled: July 17, 2020Date of Patent: January 9, 2024Assignee: BETTER WALK, INC.Inventors: Partha Sarathy Unnava, Tyler Jack Prescott Harmon